@entity505 ion radiotherapy for stage I XXXX .

@entity1 @entity55 @entity5 @entity1149 @entity505
BACKGROUND AND PURPOSE: Heavy ion radiotherapy is a promising modality because of its excellent dose localization and high biological effect on @entity5 . Using @entity505 beams, a dose escalation study was conducted for the treatment of stage I @entity1149 ( @entity1149 ) to determine the optimal dose. MATERIALS AND METHODS: The first stage phase I/II trial using 18 fractions over 6 weeks for 47 @entity1 and the second one using nine fractions over 3 weeks for 34 @entity1 were conducted by the dose escalation method from 59.4 to 95.4 Gray equivalents (GyE) in incremental steps of 10% and from 68.4 to 79.2 GyE in 5% increments, respectively. The local control and survival rates were obtained using the Kaplan-Meier method. RESULTS: Radiation @entity55 at grade III occurred in three of 81 @entity1 , but they fully recovered. This was not a dose-limiting factor. The local control rates in the first and second trials were 64% and 84%, respectively. The total recurrence rate in both trials was 23.2%. The infield local recurrence in the first trial was significantly dependent on @entity505 dose. The doses greater than 86.4 GyE at 18 fractions and 72 GyE at nine fractions achieved a local control of 90% and 95%, respectively. The 5 year overall and cause-specific survivals in 81 @entity1 were 42% and 60%, respectively. CONCLUSIONS: With our dose escalation study, the optimum safety and efficacy dose of @entity505 beams was determined. @entity505 beam therapy attained almost the same results as surgery for stage I @entity1149 although this was a I/II study.
